Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.
View Top Employees from Aduro Biotech is now Chinook TherapeuticsWebsite | http://www.aduro.com |
Ticker | ADRO |
Revenue | $15 million |
Funding | $479.6 million |
Employees | 79 (29 on RocketReach) |
Founded | 2000 |
Address | 740 Heinz Ave, Berkeley, California 94710, US |
Phone | (510) 848-4400 |
Technologies |
JavaScript,
HTML,
PHP
+46 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Business Services, Drug Manufacturing & Research, Biopharma, Health, Wellness and Fitness, Healthcare, Health Care, Science and Engineering, Life Science, Power Conversion & Protection Equipment, Electronics, Manufacturing, Education, Aerospace & Defense, Organizations |
Web Rank | 2 Million |
Keywords | Aduro Biotech, Aduro, Aduro Biotech, Inc., Aduro Biotech Inc, Cgas-Sting Video |
Competitors | Arcus Biosciences, Cidara Therapeutics, Immatics, Kiromic Biopharma, Inc., Precision Biologics |
SIC | SIC Code 37 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 5417 Companies, NAICS Code 32541 Companies |
Looking for a particular Aduro Biotech is now Chinook Therapeutics employee's phone or email?
The Aduro Biotech is now Chinook Therapeutics annual revenue was $15 million in 2023.
Obi Greenman is the Board Member of Aduro Biotech is now Chinook Therapeutics.
29 people are employed at Aduro Biotech is now Chinook Therapeutics.
Aduro Biotech is now Chinook Therapeutics is based in Berkeley, California.
The NAICS codes for Aduro Biotech is now Chinook Therapeutics are [54, 541, 325, 3254, 32, 5417, 32541].
The SIC codes for Aduro Biotech is now Chinook Therapeutics are [37, 87].